Clinical Trial Update: Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating infusion of autologous T cells engineered to target the follicle-stimulating hormone receptor (FSHR) for recurrent ovarian can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• FSH receptor-targeted autologous T cell therapy

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Ovarian Cancer | Phase 1 | Status: RECRUITING